CTS-Clinical and Translational Science

Scope & Guideline

Fostering global collaboration in clinical and translational research.

Introduction

Explore the comprehensive scope of CTS-Clinical and Translational Science through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore CTS-Clinical and Translational Science in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1752-8054
PublisherWILEY
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2008 to 2024
AbbreviationCTS-CLIN TRANSL SCI / CTS-Clin. Transl. Sci.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'CTS-Clinical and Translational Science' focuses on bridging the gap between laboratory research and clinical practice, emphasizing the importance of translational medicine in enhancing patient care and drug development.
  1. Pharmacokinetics and Pharmacodynamics:
    A core focus of the journal is the study of pharmacokinetics and pharmacodynamics, exploring how drugs are absorbed, distributed, metabolized, and excreted in various populations, including special populations such as pediatrics and those with comorbidities.
  2. Pharmacogenomics:
    The journal often publishes research on pharmacogenomics, which examines how genetic variations affect individual responses to drugs, thereby supporting personalized medicine initiatives.
  3. Clinical Trials and Drug Development:
    The journal provides insights into the design, implementation, and outcomes of clinical trials, particularly phase I studies, assessing safety and efficacy across diverse therapeutic areas.
  4. Real-World Evidence:
    A significant emphasis is placed on collecting and analyzing real-world data to complement clinical trial findings, helping to understand the effectiveness and safety of treatments in everyday clinical settings.
  5. Innovative Therapeutics:
    Research on novel therapeutic agents and drug formulations, including biosimilars and new chemical entities, is a prominent area, contributing to the advancement of treatment options for various diseases.
  6. Regulatory Science:
    The journal addresses regulatory challenges and advancements in the approval process for new therapies, ensuring that research findings are translated effectively into clinical practice.
The journal has seen a shift towards several trending and emerging themes that are gaining traction in clinical and translational research, reflecting the evolving landscape of medical science.
  1. Machine Learning and AI Applications:
    An increasing focus on the application of machine learning and artificial intelligence in predicting drug responses and personalizing treatment regimens is evident, showcasing the integration of technology in translational science.
  2. Digital Health and Remote Monitoring:
    The rise of digital health technologies, including remote patient monitoring and telemedicine, has become a prominent topic, especially in the context of the COVID-19 pandemic and its implications for healthcare delivery.
  3. Precision Medicine:
    Precision medicine continues to be a critical theme, with a growing emphasis on tailoring treatments based on genetic and phenotypic characteristics of individuals, enhancing the efficacy and safety of therapies.
  4. Regulatory Innovation:
    Research addressing innovative regulatory approaches and frameworks for expediting drug approvals and improving post-market surveillance is becoming more prevalent, reflecting the need for adaptive regulatory strategies.
  5. Real-World Data Utilization:
    The integration of real-world evidence in clinical decision-making and regulatory submissions is increasingly highlighted, demonstrating the importance of understanding treatment outcomes in broader patient populations.

Declining or Waning

While certain themes remain robust, some areas of focus within the journal appear to be declining or waning, reflecting shifts in research priorities and emerging scientific interests.
  1. Traditional Drug Interactions:
    Research specifically focused on traditional drug-drug interaction studies is less frequently published, as newer methodologies and technologies, such as pharmacogenomics and machine learning, gain prominence.
  2. General Pharmacology Studies:
    There seems to be a decrease in purely general pharmacology studies that do not incorporate translational aspects or advanced modeling techniques, as the journal shifts towards more clinically relevant applications.
  3. Single-Agent Studies:
    There is a noticeable reduction in studies evaluating single-agent therapies without considering combination therapies or multi-modal approaches, reflecting a broader trend towards integrated treatment strategies.

Similar Journals

Translational and Clinical Pharmacology

Bridging Research and Reality in Pharmacology
Publisher: KSCPTISSN: 2289-0882Frequency:

Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.

CURRENT OPINION IN PHARMACOLOGY

Connecting Researchers to the Pulse of Pharmacology
Publisher: ELSEVIER SCI LTDISSN: 1471-4892Frequency: 6 issues/year

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

BioScience Trends

Transforming Knowledge into Impactful Discoveries
Publisher: IRCA-BSSAISSN: 1881-7815Frequency: 6 issues/year

BioScience Trends, published by IRCA-BSSA, is a leading academic journal based in Japan that significantly contributes to the fields of biochemistry, genetics, molecular biology, and social health sciences. With an impactful Scopus ranking that places it in the 97th percentile for health social sciences and the 89th percentile for general biochemistry, this journal is an essential resource for researchers and professionals alike. Since its inception in 2007, BioScience Trends has fostered high-quality research dissemination and collaboration, offering a platform for innovative studies and insights that are vital for advancing knowledge in life sciences. Despite being a non-open access publication, it maintains rigorous standards and a reputable presence in the academic community, with an impressive categorization into Q1 and Q2 quartiles as of 2023. Researchers, students, and professionals seeking to stay at the forefront of scientific exploration and health advancements will find BioScience Trends to be an invaluable source for scholarly articles and emerging trends in their respective fields.

Advances in Pharmacological and Pharmaceutical Sciences

Pioneering Insights in Toxicology and Drug Development.
Publisher: HINDAWI LTDISSN: 2633-4682Frequency: 1 issue/year

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

Clinical Pharmacology-Advances and Applications

Transforming Knowledge into Clinical Applications
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1438Frequency: 1 issue/year

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

Molecular Biomedicine

Innovating Solutions through Molecular Insights
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pioneering Discoveries in Drug Behavior
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 1567-567XFrequency: 6 issues/year

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.

DRUGS IN R&D

Shaping the future of pharmacology with impactful insights.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

Future Science OA

Driving scientific dialogue for global impact.
Publisher: FUTURE SCI LTDISSN: 2056-5623Frequency: 10 issues/year

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

Clinical Pharmacology in Drug Development

Innovating therapeutics through rigorous research.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.